The European Medicines Agency will turn its EU-level trial advice pilot into a permanent option for sponsors, letting companies keep seeking regulator input as they plan studies. The change follows confirmation that the pilot program will continue beyond the initial trial phase. For biotech operators, the decision is focused on predictability in trial design—sponsors can continue to bring questions about protocols, endpoints, and development strategy to an EMA-enabled channel at EU level rather than relying on one-off pathways. The move is likely to tighten the feedback loop between early development planning and regulatory expectations, particularly for multinational programs where alignment across member states can otherwise slow execution.